Introduction
============

Recently, anti-Müllerian hormone (AMH) has been suggested as an ovarian reserve marker and predictor of ovarian response to controlled ovarian hyperstimulation (COH) in assisted reproduction cycles \[[@B1],[@B2]\]. Several investigators have demonstrated that serum AMH concentrations during the early follicular phase of the menstrual cycle decrease consistently with age in women, and the change starts at younger ages than does that of conventional markers such as FSH \[[@B3],[@B4]\]. In addition, it has been shown that the basal AMH level is correlated with antral follicle count (AFC), E~2~ level on hCG day, number of mature follicles on hCG day, and the number of oocytes retrieved after COH \[[@B1],[@B5],[@B6]\].

Although numerous studies have confirmed the usefulness of AMH as an outcome predictor, there have been no confirmed reference values of serum AMH level for prediction of ovarian response. Moreover, most studies have shown data from experimental laboratory measurements of AMH levels. Thus, the practical use of AMH was hindered by the lack of clinical data and reference values. In Korea, the clinical measurement of the serum AMH level was approved by the government and has been performed clinically in large commercial laboratory centers since 2009. In the present study, we retrospectively analyzed the clinical assay data and the relationship between serum AMH levels and ovarian response to COH and determined the cut-off value of AMH levels for predicting poor, normal, and high responders.

Methods
=======

1. Patients
-----------

We collected data from a total of 162 women who had undergone COH cycles with GnRH agonist (n=99) or GnRH antagonist (n=63) protocols. The age of the 162 women ranged from 20 to 46 years and the mean age was 35 years. The study was approved by the Institutional Review Board of Seoul National University Bundang Hospital.

2. COH protocols
----------------

For the GnRH agonist long protocol, GnRH agonist, 0.1 mg/day of triptorelin (Decapeptyl, Ferring, Malmo, Sweden) was started in the mid-luteal phase of the previous cycle. After pituitary down-regulation, the triptorelin dose was reduced to 0.05 mg/day, and gonadotropins (recombinant FSH, Gonal-F, Serono, Geneva, Switzerland; or urinary hMG, IVF-M, LG Life Science, Seoul, Korea) were added until the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm. For the GnRH antagonist protocol, gonadotropins were started on the second or third menstrual cycle day without previous oral contraceptive pretreatment. GnRH antagonist, 0.25 mg of cetrorelix (Cetrotide, Serono) was added daily, starting when the leading follicle reached a diameter of 14 mm until the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm. For both protocols, 250 µg of recombinant hCG (Ovidrel, Serono) was administered 36 hours before transvaginal oocyte retrieval. Up to four embryos were transferred 2 or 3 days after oocyte retrieval. The luteal phase was supported with 50 mg of progesterone in oil (Genefer progesterone, Genefer, Seoul, Korea) or 8% progesterone gel (Crinone, Serono) daily, initially for 14 days starting on the day of oocyte retrieval and continuing for another 6 to 8 weeks in cases where a pregnancy was achieved.

3. AMH measurement
------------------

The serum AMH level for each woman was measured with blood samples obtained on cycle day 2 or 3 before gonadotropin stimulation started. Serum samples were transferred to a commercial laboratory center and AMH was measured using enzyme-linked immunosorbent assay (ELISA, Beckman Coulter Immunotech, Marseille, France). The intra- and interassay coefficients of variation were 12.3% and 14.2%, respectively.

4. Data analysis
----------------

We collected the data on age, basal AMH and FSH levels, total dose of gonadotropins, stimulation duration, and numbers of oocytes retrieved and fertilized. The main outcome measures were serum AMH level and number of retrieved oocytes. A poor ovarian response was defined as a fewer than four oocytes and normal response as a collection of four to nineteen oocytes. Patients with more than 19 oocytes retrieved were defined as high responders. Clinical pregnancy was defined by the presence of an intrauterine gestational sac with pulsating fetal heart beats 4-5 weeks after oocyte retrieval.

Statistical analysis was performed using an analysis of variance test for continuous variables and χ^2^-test for categorical variables. Correlations between AMH and COH outcomes were determined by bivariate correlation analysis and are expressed as Pearson\'s correlation coefficients. Receiver operating characteristic curve analysis was performed and the cut-off value, sensitivity and specificity for poor and high response in AMH levels were evaluated. The SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis and the results were considered statistically significant at *p*-values of \<0.05.

Results
=======

The serum AMH levels correlated negatively with age (r=-0.447, *p*\<0.001) and positively with the number of oocytes retrieved (r=0.700, *p*\<0.001) ([Figure 1](#F1){ref-type="fig"}). [Table 1](#T1){ref-type="table"} shows the demographic and outcome parameters of the poor, normal, and high response groups. A total of 42 patients had a poor response (≤3 oocytes) to gonadotropin stimulation, while 18 had a high response (≥20 oocytes). The 102 patients had shown normal responses (4 to 19 oocytes). Basal FSH levels and stimulation days were not statistically different. However, the age, basal AMH level, total dose of gonadotropins, number of retrieved and fertilized oocytes, and clinical pregnancy rate were significantly different between the groups. The mean (±SE) serum AMH level for poor, normal, and high responses were 0.94±0.15 ng/mL, 2.79±0.21 ng/mL, and 6.94±0.90 ng/mL, respectively ([Table 1](#T1){ref-type="table"}).

Patients were further subdivided into four groups using the 25th, 50th, and 75th percentiles according to AMH values (0.85 ng/mL, 1.89 ng/mL, and 3.64 ng/mL, respectively). Except for stimulation duration, the outcome parameters of COH were also significantly different according to the quartile AMH levels ([Table 2](#T2){ref-type="table"}).

The AMH levels performed well in prediction of poor and high response after COH (AUC 0.869, *p*\<0.001; AUC 0.912, *p*\<0.001 for poor and high response, respectively). The cut-off level, sensitivity, and specificity for poor and high response were 1.08 ng/mL, 85.8%, and 78.6%; and 3.57 ng/mL, 94.4%, and 83.3%, respectively ([Table 3](#T3){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}).

Discussion
==========

In this study, we confirmed the usefulness of AMH as a predictor of ovarian response to COH. The serum AMH level was significantly different according to the ovarian response to COH in contrast to FSH, which showed no difference among the poor, normal, and high response groups. In addition, we determined the cut-off values of AMH levels for poor and high ovarian responders among Korean women with clinical assay data. The cut-off levels we presented in this study show good concordance with the values presented in other recent studies \[[@B7]-[@B14]\]. This means that the cut-off values measured by clinical assay correlate well with the values measured in each research laboratory.

Currently, the AMH value has been suggested as an ovarian reserve marker \[[@B1],[@B2],[@B5],[@B9]\]. Before the studies of AMH were published, other conventional methods had been developed for predicting ovarian reserve such as early follicular FSH, E~2~, and the clomiphene challenge test. However, these traditional assessments have low sensitivity in the early stages of reduced ovarian reserve \[[@B15]\]. Several authors have reported that AFC yields the best prognostic information with regard to the occurrence of poor response in IVF \[[@B5],[@B16]\]. However, AFC has the limitation of high inter-observer variability due to the duration of the vaginal ultrasound examination, observers\' experiences and, notably, expected ovarian reserve due to the patient\'s age \[[@B9]\]. Recently, AMH was also found to have predictive performance comparable with that of AFC \[[@B5],[@B17]\]. There are advantages to the use of AMH over other markers since there are relatively minimal intra- and inter-cycle variations in serum levels. Therefore AMH can be measured throughout the cycle in contrast to the other markers, which would only be checked during the early follicle phase \[[@B5],[@B18],[@B19]\]. Moreover, AMH levels can be obtained by objective measurements performed in a well-controlled laboratory and thus are free of inter-observer variability, which is shown in AFC measurements \[[@B20]\].

To date, many studies have reported various cut-off levels of AMH, but there is no consensus on cut-off values for predicting poor or high response to COH. This discrepancy may be due to the different criteria for poor responses, different study populations, and different sampling days. Using different types of ELISA kits, the Immunotech Beckman Coulter kit or the Diagnostic Systems Laboratories kit, for measuring AMH levels was has also been suggested as one of the causes. Those two types of kits are commercially available and used in almost all published studies. Several studies have compared the two kits, but the results have been inconsistent. Fréour et al. \[[@B21]\] and Bersinger et al. \[[@B22]\] reported that there were discordances between the AMH levels measured by the two kits and that they were due to the lack of an international standard and residual matrix effects. However, recent studies have shown that the AMH levels measured by the two kits are not different and concluded that similar reference values could be used with both kits \[[@B23],[@B24]\]. La Marca et al. \[[@B25]\] suggested that the methological problems that were observed in earlier studies could have been solved by the manufacturers. Therefore, it was concluded that, at least in recent studies, using different types of kits is not the cause of discrepancies in cut-off values of AMH. Indeed, the cut-off values of AMH for poor or high response to COH reported in recent studies have been within a small range. The currently reported cut-off values were 0.99 to 1.40 ng/mL for poor responders \[[@B7]-[@B9],[@B14],[@B21],[@B26]\] and 3.36-3.55 ng/mL for high responders \[[@B11],[@B13],[@B14]\]. In our study, the cut-off values of AMH were 1.08 ng/mL and 3.57 ng/mlL, respectively, which are similar with the results of recent studies. This means that the cut-off values measured in the clinical assays correlate well with the values measured previously in each research laboratory.

In the present study, women who underwent GnRH agonist or GnRH antagonist protocol were included, but COH outcomes such as the number of oocytes retrieved, number of fertilized oocytes, and clinical pregnancy rate were not significantly different (data not shown). This result is in line with that of a previous study that showed that serum and follicular fluid AMH levels and COH outcomes did not differ between the two protocols \[[@B6]\].

The pretreatment prediction of ovarian reserve in IVF patients allows for appropriate counseling and modification of an individual\'s treatment protocol, thereby maximizing their chances of a successful outcome \[[@B27]-[@B29]\]. We believe that ovarian reserve testing using AMH is likely to become a routine practice in the evaluation of infertile couples \[[@B5],[@B28]\]. The augmentation of the starting dose of gonadotropins can be attempted for poor responders. On the other hand, a low gonadotropin dose can be used to reduce the incidence of OHSS for patients with high serum AMH levels \[[@B30]\]. The clinical usefulness of AMH has been confirmed by numerous studies using research data. In this study, we also confirmed the clinical value of AMH by clinically measured data. Therefore, the clinical measurement of AMH is a feasible method for ovarian reserve testing and the measurement has a good value for the government approval of clinical assay as approved by the Korean government in 2009. In conclusion, the cut-off values measured in clinical assay correlate well with the previously reported values measured in research laboratories. Our data present clinical reference values of serum AMH level for ovarian response and these cut-off levels could be used practically to predict poor or high response to COH. The government approval of AMH measurement helps to make the AMH used more widely in clinical situations.
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Demographic and outcome parameters according to ovarian response
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Values are presented as mean±SD except AMH (mean±SE).

OPU, number of oocytes retrieved; AMH, anti-Müllerian hormone.

^a,b,c^Different letters indicate significant differences.
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Demographic and outcome parameters according to quartile AMH level
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Values are presented as mean±SD.

AMH, anti-Müllerian hormone.

^a,b,c,d^Different letters indicate significant differences.
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Results of the receiver operating characteristics curve analysis of serum AMH concentration discriminating for controlled ovarian stimulation outcomes
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AMH, anti-Müllerian hormone; AUC, area under the curve; CI, confidence interval; OPU, number of oocytes retrieved.
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